Human Liver Regeneration Associated Protein and the Use Thereof
AssigneeShanghai Institutes for Biological Sciences, Chinese Academy of Sciences
InventorsMujun Zhao, Liu Zhanwu, Qiu Jie, Li Zaiping
Life of this patent
Estimating the term…
Abstract
This invention provides a novel human liver regeneration associated protein hLRTM4 and the polynucleotide which encodes the hLRTM4 protein. Furthermore, this invention provides a method of preparing and using hLRTM4 protein and its polynucleotides. hLRTM4 protein can be used to treat liver injury, and its antagonists (e.g. antisense nucleic acids and antibodies) can be used to treat hepatocellular carcinoma. This invention also provides the corresponding pharmaceutical compositions.
Claims10
A pharmaceutical composition comprising a safe and effective amount of human liver regeneration associated protein hLRTM4, and a pharmaceutically acceptable vehicle, diluent or carrier.
A use of liver regeneration associated protein hLRTM4 in the preparation of a drug used for treating liver injury.
A pharmaceutical composition comprising a safe and effective amount of antagonists of hLRTM4 protein, wherein the antagonists are selected from the group consisting of:
- (i) an antisense polynucleotide to hLRTM4 , wherein the polynucleotide has the antisense nucleotide sequence as shown in SEQ ID NO:
- 1 and has a length of 15-625 bp, (ii)small interfering double-strand RNAs of hLRTM4, wherein the RNAs have the nucleotide sequence as shown in SEQ ID NO:1 and have a length of 17-23 bp and a 3′-terminal dtdt sequence;
- and/or (iii) a specific antibody against hLRTM4, as well as a pharmaceutically acceptable vehicle, diluent or carrier.
A use of hLRTM4 protein antagonist for the preparation of a drug for treating hepatocellular carcinoma, wherein the antagonist is selected from:
- (i) an antisense polynucleotide to hLRTM4, wherein the polynucleotide has the nucleotide sequence as shown in SEQ ID NO:
- 1 and has a length of 15-625 bp;
- (ii) a small interfering double-strand RNA of hLRTM4, wherein the RNA has the nucleotide sequence as shown in SEQ ID NO:1 and has a length of 17-23 bp and a 3′-terminal dtdt sequence;
- and/or (iii) a specific antibody against hLRTM4.
Dependencies are inferred from the claim text.